Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insight Molecular DiagnosticsIMDX +3.14%49 Days Sales Outstanding is 66.62 as of Jun. 2026, which is 61% below its 10-year median of 169.82. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks worse than 68.32% on this metric.
The historical rank and industry rank for Insight Molecular Diagnostics's Days Sales Outstanding or its related term are showing as below:
IMDX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.93 Med: 169.82 Max: 657.04
Current: 98.22
During the past 13 years, Insight Molecular Diagnostics's highest Days Sales Outstanding was 657.04. The lowest was 60.93. And the median was 169.82.
IMDX's Days Sales Outstanding is ranked worse than 68.32% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.855
vs IMDX: 98.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Days Sales Outstanding Chart
IMDX vs XGN, BNR, BDSX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Days Sales Outstanding falls into.
Insight Molecular Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Days Sales Outstanding of 66.62 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Insight Molecular Diagnostics and its competitors. This is 61% below median its historical median of 169.82. Over the past decade, Insight Molecular Diagnostics' Days Sales Outstanding has ranged from 60.93 to 657.04. According to the industry distribution chart, Insight Molecular Diagnostics ranks #138 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 68.3%.
Is Insight Molecular Diagnostics' Days Sales Outstanding too high?
Insight Molecular Diagnostics' current Days Sales Outstanding of 66.62 is 61% below median its 10-year median of 169.82. Over the past 10 years, this metric has ranged from a low of 60.93 to a high of 657.04. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.86. Insight Molecular Diagnostics' value of 66.62 is 1.8% below this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #138 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Days Sales Outstanding compare to XGN and BNR?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #138 out of 202 companies for Days Sales Outstanding. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median Days Sales Outstanding is 67.86. Insight Molecular Diagnostics' value of 66.62 is 1.8% below this benchmark. Historically, Insight Molecular Diagnostics' own Days Sales Outstanding has ranged from 60.93 to 657.04 over the past decade. While the company's 10-year median is 169.82 vs. the industry median of 67.86, Insight Molecular Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Days Sales Outstanding of 66.62 is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Days Sales Outstanding is 66.62, which is 61% below median its own 10-year median of 169.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.08, compared to a current price of $4.45 — trading 311.6% above its estimated fair value. The current Days Sales Outstanding is 66.62, which is 61% below median its 10-year median of 169.82 and 1.8% below the Medical Diagnostics & Research industry median of 67.86. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Days Sales Outstanding is 66.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $4.45 is trading 311.6% above its estimated GF Value™ of $1.08.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Days Sales Outstanding: 66.62 (61% below median its 10-year median of 169.82)
GF Value™: $1.08 vs. price of $4.45 (311.6% above fair value)
Industry Position: 1.8% below the Medical Diagnostics & Research median (#138 of 202)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
